17 October 2024 The chronic obstructive pulmonary disease (COPD) market in the seven major markets (7MM) is set to grow from $11.5 billion in 2023 to $30.8 billion in 2033, driven by the launch of the first biologic for COPD and other pioneering pipeline agents.
As the European Parliament prepares for the confirmation hearings of the new Commissioners, the Open Trade Coalition is reiterating its call for a bold and open EU trade policy, according to a posting on the European Federation of Pharmaceutical Industries and Associations (EFPIA) website. 18 October 2024
After a couple of negative decisions, the US Food and Drug Administration (FDA) has approved Vyalev (foscarbidopa and foslevodopa) as the first and only subcutaneous 24-hour infusion of levodopa-based therapy for the treatment of motor fluctuations in adults with advanced Parkinson's disease (PD). 18 October 2024
Gan & Lee Pharmaceuticals as reported that its three investigational drugs - GZR18, GZR4, and GZR101 - achieved positive results in Phase II diabetes trials. 17 October 2024
A new group of British Members of Parliament (MPs) and peers have written to the Chancellor urging her to protect and promote the UK’s world-leading life sciences sector in the government's first Budget, due on October 30. 17 October 2024
The US Food and Drug Administration (FDA) has updated the US label for French pharma major Sanofi’s Flublok (Influenza Vaccine) to include data from a new safety study involving pregnant women. 17 October 2024
Chengdu Baiyu Pharmaceutical yesterday announced that it has entered into an exclusive license agreement with Swiss pharma giant Novartis for a small molecule anti-tumor asset. 17 October 2024
Shionogi has announced new data at IDWeek 2024 from PROVE (Retrospective Cefiderocol Chart Review), the largest global real-world evidence study of Fetroja/Fetcroja (cefiderocol), an innovative siderophore cephalosporin. 17 October 2024
Sanofi has entered into an agreement with Orano Med, a subsidiary of the Orano Group, to advance the development of radioligand therapies for rare cancers. 17 October 2024
ViiV Healthcare, the specialist HIV company majority owned by GSK, today announced the presentation of new real-world evidence and implementation data showing the effectiveness, adherence, and quality-of-life improvement of Apretude (cabotegravir long-acting (CAB LA)) for HIV pre-exposure prophylaxis (PrEP). 16 October 2024
Jaguar Health today announced the US launch of Gelclair, the only Food and Drug Administration (FDA)-approved mucoadhesive on the market indicated for the management of pain caused by oral mucositis 16 October 2024
Netherlands-based life sciences venture capital firm Forbion has raised more than 2 billion euros ($2.2 billion) across its two newest funds. 16 October 2024
The American Lung Association Research Institute has announced a $22 million research investment in 2024, marking one of the largest lung health research programs in the USA. 16 October 2024
US pharma major Eli Lilly has announced a strategic collaboration with two UK government departments and the devolved nations to tackle significant population health challenges, including exploring new models to better care for people living with obesity. 16 October 2024
TenNor Therapeutics, a Suzhou-based clinical-stage biotech company, has announced the initial closing of a series E financing round, raising over 300 million yuan ($41 million). 16 October 2024
Switzerland-based Novocure saw its shares rise 10% yesterday and leap a further 24% to $22.05 pre-market, after the company received a new US regulatory approval for its key product Optune Lua. 16 October 2024
Shares of Spanish drugmaker PharmaMar leapt more than 28% to 63.70 euros today, after it announced positive clinical trial findings for its combo lung cancer treatment, under development with USA-based Jazz Pharmaceuticals, which rose 4.2%. 15 October 2024
Due to Russia’s military invasion of the Ukraine, global pharma companies are massively refusing to conduct clinical trials of their drugs in Russia, which means that the launch of these drugs in the local market will be impossible 19 March 2022
The British business of Japanese pharma major Takeda Pharmaceutical has secured conditional approval in the UK for its first-in-class oral tyrosine kinase inhibitor (TKI) Exkivity (mobocertinib). 18 March 2022
An Expert View from Jennifer Romanski, a principal of Porzio, Bromberg & Newman and a co-chair of its Life Sciences Compliance and Regulatory Counseling Department. She is also a senior vice president at Porzio Life Sciences, a wholly-owned subsidiary of the law firm. 18 March 2022
China’s Ignis Therapeutics and Germany’s STADA Arzneimittel’s Britannia Pharmaceuticals UK affiliate today jointly announced the signing of an exclusive licensing agreement under which Ignis Therapeutics will develop and commercialize subcutaneous apomorphine for Parkinson's disease in mainland China, Hong Kong and Macau. 18 March 2022
Following the release of a draft text for the World Trade Organization (WTO)-led waiver on intellectual property (IP) for COVID-19 vaccines, the European Federation of Pharmaceutical Industries and Associations (EFPIA) calls on governments across Europe and around the world to urgently rethink discussions on a COVID vaccine waiver and instead focus on the real barriers to global vaccine equity. 18 March 2022
In Germany and France, a new research collaboration will investigate the neurodegenerative disease spinocerebellar ataxia type 3 (SCA3), in collaboration with Servier Laboratories. 18 March 2022
Shares of CNS focussed US pharma firm Impel NeuroPharma were up 5.3% at $6.98 early afternoon, having risen as high as $7.24, after it announced two separate transactions with funds managed by Oaktree Capital Management, totaling $100 million in gross funding. 17 March 2022
Boston, USA-based pricing watchdog The Institute for Clinical and Economic Review (ICER) has published a revised assessment of the relative merits of two possible competitors in hematology. 17 March 2022
Privately-held Danish dermatology specialist LEO Pharma today report financials for full-year 2021, noting that net sales grew 5% to 9,957 million kroner ($1.47 billion) when excluding discontinued and divested products. 17 March 2022
Swiss biopharma Relief Therapeutics’ subsidiary, APR Applied Pharma Research, has reported final data from its clinical trial of nasal spray, Sentinox, in SARS-CoV-2 infected patients. 17 March 2022
Australian cancer patients will get improved access to local clinical trials through a new public-private partnership consortium, PrOSPECT, which today announced a funding agreement that is expected to enable a significant increase in local cancer clinical trial participation. 17 March 2022
Although Japanese drugmakers have been lagging behind the USA and Europe in the search for and launch of COVID-19 treatments and vaccines, Shionogi seems to be picking up momentum. 16 March 2022
The EMPA-KIDNEY trial, evaluating the effect of Jardiance (empagliflozin) in adults with chronic kidney disease (CKD), will stop early based on a recommendation from the trial’s Independent Data Monitoring Committee. 16 March 2022
At the annual congress of the Muscular Dystrophy Association (MDA), Swiss pharma giant Roche has announced new data for its spinal muscular atrophy (SMA) drug Evrysdi (risdiplam). 16 March 2022
Israeli specialty drugmaker RedHill Biopharma has entered into an exclusive license agreement with Kukbo Co (Kospi: 001140), a South Korean corporation, for oral opaganib for the treatment of COVID-19, in South Korea. 15 March 2022
Global drugmakers have no plans to leave Russia, aiming to continue their work in the local market despite the ongoing military escalation in Ukraine and unprecedented sanctions imposed on the country by Western governments, according to recent statements by representatives of companies and some local media, reports The Pharma Letter’s local correspondent. 15 March 2022
Just last week, Astellas Pharma announced positive top-line results from the Phase III SKYLIGHT 4 trial investigating fezolinetant in moderate to severe vasomotor symptoms associated with menopause (VMS). 15 March 2022
Australia’s Therapeutic Goods Administration (TGA) has approved the use of single-dose Kozenis (tafenoquine) in children aged two years and above in combination with chloroquine for the radical cure (prevention of relapse) of Plasmodium vivax (P. vivax) malaria. 14 March 2022
Outlining an update to its business strategy, Swedish immunology company InDex Pharmaceuticals says it plans to take on US commercialization of cobitolimod itself. 14 March 2022
Japanese firm Mitsubishi Tanabe has submitted to the Ministry of Health, Labor and Welfare in Japan an application for the manufacturing and marketing approval of an investigational oral formulation of edaravone (MT-1186) for the treatment of amyotrophic lateral sclerosis (ALS). 14 March 2022
Sign up to receive email updates Join industry leaders for a daily roundup of biotech & pharma news
Company Spotlight
Dewpoint is a biotech company pioneering the application of biomolecular condensate biology – the science studying the organization of biomolecules within membrane-less compartments – towards the development of a new generation of therapeutics to address diseases of high unmet need.